Chimatahalli Shanthakumar K, Sridhara P, Rajabathar J, Al-Lohedan H, Lokanath N, Mylnahalli Krishnegowda H
ACS Omega. 2024; 9(19):20753-20772.
PMID: 38764648
PMC: 11097344.
DOI: 10.1021/acsomega.3c07520.
Singh S, Singh P, Sachan K, Kumar M, Bhardwaj P
Curr Comput Aided Drug Des. 2023; 20(6):723-735.
PMID: 37807412
DOI: 10.2174/0115734099260187230921073932.
Azizogli A, Pai V, Coppola F, Jafari R, Dodd-O J, Harish R
ACS Omega. 2023; 8(6):5349-5360.
PMID: 36798146
PMC: 9923439.
DOI: 10.1021/acsomega.2c06384.
Vanangamudi M, Nair P, Engels S, Palaniappan S, Namasivayam V
Adv Exp Med Biol. 2021; 1322:63-95.
PMID: 34258737
DOI: 10.1007/978-981-16-0267-2_3.
Zhang J, Vernon K, Li Q, Benko Z, Amoroso A, Nasr M
Pathogens. 2021; 10(7).
PMID: 34202872
PMC: 8308830.
DOI: 10.3390/pathogens10070804.
Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors.
Ghosh A, Brindisi M
Asian J Org Chem. 2019; 7(8):1448-1466.
PMID: 31595212
PMC: 6781882.
DOI: 10.1002/ajoc.201800255.
3'-Tetrahydrofuranylglycine as a Novel, Unnatural Amino Acid Surrogate for Asparagine in the Design of Inhibitors of the HIV Protease.
Thompson W, Ghosh A, Holloway M, Lee H, Munson P, Schwering J
J Am Chem Soc. 2018; 115(2):801-803.
PMID: 30364398
PMC: 6196357.
DOI: 10.1021/ja00055a069.
Application of computational methods for anticancer drug discovery, design, and optimization.
Prada-Gracia D, Huerta-Yepez S, Moreno-Vargas L
Bol Med Hosp Infant Mex. 2018; 73(6):411-423.
PMID: 29421286
PMC: 7110968.
DOI: 10.1016/j.bmhimx.2016.10.006.
Dynamic undocking and the quasi-bound state as tools for drug discovery.
Ruiz-Carmona S, Schmidtke P, Luque F, Baker L, Matassova N, Davis B
Nat Chem. 2017; 9(3):201-206.
PMID: 28221352
DOI: 10.1038/nchem.2660.
Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance.
Nakashima M, Ode H, Suzuki K, Fujino M, Maejima M, Kimura Y
Front Microbiol. 2016; 7:61.
PMID: 26870021
PMC: 4737996.
DOI: 10.3389/fmicb.2016.00061.
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.
Ghosh A, Osswald H, Prato G
J Med Chem. 2016; 59(11):5172-208.
PMID: 26799988
PMC: 5598487.
DOI: 10.1021/acs.jmedchem.5b01697.
HIV protease inhibitors: a review of molecular selectivity and toxicity.
Lv Z, Chu Y, Wang Y
HIV AIDS (Auckl). 2015; 7:95-104.
PMID: 25897264
PMC: 4396582.
DOI: 10.2147/HIV.S79956.
Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency.
Goldfarb N, Ohanessian M, Biswas S, McGee Jr T, Mahon B, Ostrov D
Biochemistry. 2014; 54(2):422-33.
PMID: 25513833
PMC: 4303317.
DOI: 10.1021/bi501088e.
Evaluation of novel Saquinavir analogs for resistance mutation compatibility and potential as an HIV-Protease inhibitor drug.
Jayaswal A, Mishra A, Mishra H, Shah K
Bioinformation. 2014; 10(4):227-32.
PMID: 24966525
PMC: 4070054.
DOI: 10.6026/97320630010227.
A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid.
Lee S, Cheng N, Hull-Ryde E, Potempa M, Schiffer C, Janzen W
Biochemistry. 2013; 52(29):4929-40.
PMID: 23763575
PMC: 3855639.
DOI: 10.1021/bi4005232.
Trendspotting in the Protein Data Bank.
Berman H, Narayanan B, Di Costanzo L, Dutta S, Ghosh S, Hudson B
FEBS Lett. 2013; 587(8):1036-45.
PMID: 23337870
PMC: 4068610.
DOI: 10.1016/j.febslet.2012.12.029.
Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease.
King N, Prabu-Jeyabalan M, Bandaranayake R, Nalam M, Nalivaika E, Ozen A
ACS Chem Biol. 2012; 7(9):1536-46.
PMID: 22712830
PMC: 3594831.
DOI: 10.1021/cb300191k.
Protein pharmacophore selection using hydration-site analysis.
Hu B, Lill M
J Chem Inf Model. 2012; 52(4):1046-60.
PMID: 22397751
PMC: 3422394.
DOI: 10.1021/ci200620h.
Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.
Ghosh A, Anderson D, Weber I, Mitsuya H
Angew Chem Int Ed Engl. 2012; 51(8):1778-802.
PMID: 22290878
PMC: 7159617.
DOI: 10.1002/anie.201102762.
Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease.
Ozer N, Schiffer C, Haliloglu T
Biophys J. 2010; 99(5):1650-9.
PMID: 20816079
PMC: 2931728.
DOI: 10.1016/j.bpj.2010.06.064.
